Evidence map›Paper›PMID 25876464›Full record

ArticleGene therapy2015

Lister strain vaccinia virus with thymidine kinase gene deletion is a tractable platform for development of a new generation of oncolytic virus.

J Hughes, P Wang, G Alusi, H Shi, Y Chu, J Wang, V Bhakta, I McNeish, A McCart, N R Lemoine and 1 more

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Gene therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. A new oncolyticJournal for immunotherapy of cancer · 2020
    Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 3 countries.

J HughesCentre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.
P WangSino-British Research Centre for Molecular Oncology, Zhengzhou University, Zhengzhou, China.
G AlusiCentre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.
H ShiSino-British Research Centre for Molecular Oncology, Zhengzhou University, Zhengzhou, China.
Y ChuSino-British Research Centre for Molecular Oncology, Zhengzhou University, Zhengzhou, China.
J WangSino-British Research Centre for Molecular Oncology, Zhengzhou University, Zhengzhou, China.
V BhaktaCentre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.
I McNeishCentre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.ORCID 0000000293877586
A McCart1] Department of Surgery, University of Toronto, Toronto, ON, Canada [2] Division of Experimental Therapeutics, Toronto-General Research Institute, Toronto, ON, Canada.
N R Lemoine1] Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK [2] Sino-British Research Centre for Molecular Oncology, Zhengzhou University, Zhengzhou, China.
Y Wang1] Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK [2] Sino-British Research Centre for Molecular Oncology, Zhengzhou University, Zhengzhou, China.ORCID 0000000323676313
Queen Mary University of London · GBZhengzhou University · CNUniversity of Toronto · CA

Funding

Cancer Research UK 12008
6 · The paper itself

Abstract

Vaccinia virus (VV) has many attractive characteristics as a potential cancer therapeutic. There are several strains of VV. The nonvaccine strain Western Reserve VV with deletion of both the thymidine kinase and the viral growth factor genes (known as WRDD) has been reported as the most potent tumor-targeted oncolytic VV. Other strains, such as the European vaccine Lister strain, are largely untested. This study evaluated the antitumor potency and biodistribution of different VV strains using in vitro and in vivo models of cancer. Lister strain virus with thymidine kinase gene deletion (VVΔTK) demonstrated superior antitumor potency and cancer-selective replication in vitro and in vivo, compared with WRDD, especially in human cancer cell lines and immune-competent hosts. Further investigation of functional mechanisms revealed that Lister VVΔTK presented favorable viral biodistribution within the tumors, with lower levels of proinflammatory cytokines compared with WRDD, suggesting that Lister strain may induce a diminished host inflammatory response. This study indicates that the Lister strain VVΔTK may be a particularly promising VV strain for the development of the next generation of tumor-targeted oncolytic therapeutics.

Indexed as

Gene DeletionAnimalsCell LineCell Line, TumorChlorocebus aethiopsDisease Models, AnimalGenetic TherapyHumansKidneyMiceMutationNeoplasmsOncolytic VirusesSmallpox VaccineThymidine KinaseVaccinia virusSmallpox VaccineThymidine Kinase

Identifiers

PMID25876464
OpenAlexW1993700109

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.